Pancreatic Cancer Research

ResearcherNagoya University HospitalActive in the last 2 years

Osamu Maeda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4700-6541; OpenAlex author ID A5084402247. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: none · 2026: 3 papers

Papers 9

  1. Clinical Outcomes of Gemcitabine Plus Nab-Paclitaxel-Based Chemoradiotherapy in a Multidisciplinary Treatment Strategy for Locally Advanced Pancreatic Cancer (… Co-author DOI 10.1002/ijc.70801↗
  2. Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine With Nab-Paclitaxel) for Borderline-Resectable Pancreatic Cancer: Long-Term Results of a Randomized Control… Co-author DOI 10.1002/jhbp.70150↗
  3. FOLFIRINOX vs. Gemcitabine/Nab-Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C-CAT Database Study. Co-author DOI 10.1111/cas.70351↗
  4. Impact of sarcopenia on biliary drainage during neoadjuvant therapy for pancreatic cancer. Co-author DOI 10.5946/ce.2022.278↗
  5. Selection of chemotherapy for older patients with pancreatic cancer based on geriatric assessment. Co-author DOI 10.1016/j.jgo.2022.09.005↗
  6. Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01). Co-author DOI 10.1097/sla.0000000000005430↗
  7. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 … Co-author DOI 10.18999/nagjms.81.2.233↗
  8. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer. Co-author DOI 10.1007/s00280-018-3554-3↗
  9. Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction. Co-author DOI 10.1111/cas.12851↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroki Kawashima · 8 shared papers, 2018–2026 · strength 1.45
  2. Takuya Ishikawa · 6 shared papers, 2019–2026 · strength 1.16
  3. Junpei Yamaguchi · 6 shared papers, 2018–2026 · strength 0.97
  4. Yukihiro Yokoyama · 6 shared papers, 2018–2026 · strength 0.97
  5. Tomoki Ebata · 5 shared papers, 2016–2026 · strength 0.90
  6. Suguru Yamada · 4 shared papers, 2018–2026 · strength 0.56
  7. Eizaburo Ohno · 4 shared papers, 2019–2024 · strength 0.54
  8. Tsutomu Fujii · 4 shared papers, 2018–2026 · strength 0.49
  9. Yasuhiro Kodera · 4 shared papers, 2018–2024 · strength 0.46
  10. Masamichi Hayashi · 3 shared papers, 2018–2026 · strength 0.36
  11. Shinji Naganawa · 3 shared papers, 2018–2026 · strength 0.36
  12. Yuichi Ando · 1 shared paper, 2026 · strength 0.33
  13. Kazuyuki Mizuno · 1 shared paper, 2026 · strength 0.33
  14. Yukio Ando · 4 shared papers, 2016–2022 · strength 0.33
  15. Mitsuro Kanda · 1 shared paper, 2026 · strength 0.22
  16. Haruyoshi Tanaka · 1 shared paper, 2026 · strength 0.22
  17. Nobuhiko Nakagawa · 1 shared paper, 2026 · strength 0.22
  18. Hironori Yamada · 1 shared paper, 2026 · strength 0.22
  19. Masato Nagino · 3 shared papers, 2016–2019 · strength 0.19
  20. Tadashi Iida · 1 shared paper, 2024 · strength 0.19
  21. Kunio Kataoka · 1 shared paper, 2024 · strength 0.19
  22. Yasuyuki Mizutani · 1 shared paper, 2024 · strength 0.19
  23. Kentaro Yamao · 1 shared paper, 2024 · strength 0.19
  24. Masato Nagino · 1 shared paper, 2022 · strength 0.14
  25. Hidemi Goto · 2 shared papers, 2018–2019 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.